指南与共识乳腺癌

中国晚期三阴性乳腺癌临床诊疗指南(2024版)

[Guidelines for clinical diagnosis and treatment of advanced triple negative breast cancer in China(2024 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2024-01-01

乳腺癌居全球女性恶性肿瘤首位,2020年中国年龄标化发病率为39.1/10万,新发41.6万例,占全球18.4%。三阴性乳腺癌恶性程度高、预后差,晚期治疗手段有限。中国抗癌协会乳腺癌专业委员会等倡导多学科专家依据最新循证证据制定本指南,旨在优化中国晚期三阴性乳腺癌精准治疗决策。

要点

  • 2020年中国乳腺癌年龄标化发病率为39.1/10万,新发41.6万例,占全球18.4%。
  • 三阴性乳腺癌恶性程度高、预后较差,晚期治疗手段相对有限、有待优化。
  • 指南由多学科专家组依据最新循证证据制定,旨在优化晚期三阴性乳腺癌精准治疗决策。

核心结论

  • 中国多学科专家组依据最新循证证据达成共识,制定本指南以指导或优化中国晚期三阴性乳腺癌的精准治疗决策。

研究设计与样本

  • 由中国抗癌协会乳腺癌专业委员会、中国抗癌协会国际医疗交流分会和中国医师协会肿瘤医师分会乳腺癌学组倡导,中国乳腺癌各学科诊疗专家组制定。

主要发现

  • 2020年GLOBOCAN数据显示乳腺癌首次超过肺癌成为全球第一高发恶性肿瘤。
  • 中国2020年年龄标化乳腺癌发病率为39.1/10万,新发乳腺癌41.6万例,占全球每年新发乳腺癌总人数的18.4%。
  • 三阴性乳腺癌是恶性程度高、预后较差的亚型,因以往缺乏明确治疗靶点,近年治疗进展缓慢。
  • 晚期三阴性乳腺癌治疗手段相对有限,存在巨大的治疗优化未满足需求。

关键数值与推荐

  • 中国2020年年龄标化乳腺癌发病率为39.1/10万。
  • 中国2020年新发乳腺癌41.6万例,占全球每年新发乳腺癌总人数的18.4%。

临床怎么用

  • 原文未据此给出具体推荐条款。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer ranks as the most common female malignancy worldwide. Data from GLOBOCAN 2020 showed that breast cancer surpassed lung cancer and become the leading malignancy globally which was a serious threat to women's health. Different from Caucasian, there is a lower prevalence of breast cancer in Chinese women. But the age-standardized incidence rate of breast cancer in China has reached to 39.1 per 100,000 in 2020, with 416,000 new cases, accounting for 18.4% of global breast cancer burden, due to multiple factors such as lifestyle and dietary habits changes in recent years[1]. The treatment and prevention of breast cancer are becoming increasingly a tuff task. In addition, triple-negative breast cancer (TNBC) is a subtype with higher malignancy and worse prognosis. Due to lack of specific therapeutic targets, less treatment progress has been made in recent years. There is even less progress in the therapy of advanced TNBC, but huge unmet needs exist for further therapeutic optimization. Echoing advocacy from The Society of Breast Cancer China Anti-Cancer Association; International Medical Exchange Society, Chinese Anti-Cancer Association; Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association, top experts from multidisciplinary departments of breast cancer in China have consensus on this "Guidelines for Clinical Diagnosis and Treatment of Advanced Triple-Negative Breast Cancer in China (2024 Edition)" according to the latest evidence based updates. We hope this pater can guide or optimize the precise therapeutic decision-making for advanced triple-negative breast cancer in China. 乳腺癌是全球女性最常见的恶性肿瘤,2020年GLOBOCAN流行病学数据显示,乳腺癌首次超过肺癌成为全球第一高发的恶性肿瘤,严重威胁女性健康。相较于欧美人群,中国女性患者的乳腺癌发病率相对较低,但是随着近年来生活方式、饮食习惯的改变等,中国人群乳腺癌发病逐年增加。中国2020年年龄标化的乳腺癌发病率达到39.1/10万,新发乳腺癌达41.6万例,占全球每年新发乳腺癌总人数的18.4%。乳腺癌防治工作也日益严峻,其中,三阴性乳腺癌作为一种恶性程度高、预后较差的乳腺癌亚型,由于以往缺乏明确的治疗靶点,近年来治疗进展缓慢。尤其是晚期三阴性乳腺癌的治疗,由于治疗手段相对有限,有待进一步优化治疗建议。因此,在中国抗癌协会乳腺癌专业委员会、中国抗癌协会国际医疗交流分会和中国医师协会肿瘤医师分会乳腺癌学组的倡导下,中国乳腺癌各学科诊疗专家组结合国内外最新研究证据、治疗理念和经验,制定了中国晚期三阴性乳腺癌临床诊疗指南(2024版),旨在优化中国晚期三阴性乳腺癌精准治疗决策。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Guidelines for clinical diagnosis and treatment of advanced triple negative breast cancer in China(2024 edition)]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 38527739. doi:10.3760/cma.j.cn112152-20240118-00034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。